Evidence map›Paper›PMID 27705947›Full record

ArticleOncotarget2016

MiRNA203 suppresses the expression of protumorigenic STAT1 in glioblastoma to inhibit tumorigenesis.

Chuan He Yang, Yinan Wang, Michelle Sims, Chun Cai, Ping He, Junming Yue, Jinjun Cheng, Frederick A Boop, Susan R Pfeffer, Lawrence M Pfeffer

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. OncoTargets and therapy · 2017
    Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Chuan He YangDepartment of Pathology and Laboratory Medicine, University of Tennessee Health Science Center, Memphis, Tennessee.
Yinan WangDepartment of Pathology and Laboratory Medicine, University of Tennessee Health Science Center, Memphis, Tennessee.
Michelle SimsDepartment of Pathology and Laboratory Medicine, University of Tennessee Health Science Center, Memphis, Tennessee.
Chun CaiCenter for Cancer Research, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Ping HeCenter for Cancer Research, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Junming YueDepartment of Pathology and Laboratory Medicine, University of Tennessee Health Science Center, Memphis, Tennessee.
Jinjun ChengDepartment of Pathology and Laboratory Medicine, University of Tennessee Health Science Center, Memphis, Tennessee.
Frederick A BoopDepartment of Neurosurgery, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Susan R PfefferDepartment of Pathology and Laboratory Medicine, University of Tennessee Health Science Center, Memphis, Tennessee.
Lawrence M PfefferDepartment of Pathology and Laboratory Medicine, University of Tennessee Health Science Center, Memphis, Tennessee.
Center for Cancer Research · USUniversity of Tennessee Health Science Center · USChina Medical University · CN

Funding

Strategies to improve the antiglioma action of IFN-?: a role for NF-kB inhibitionR01CA133322 · NCI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI DAVIDOFF, ANDREW M, PFEFFER, LAWRENCE MARC · 2009 to 2013
$2.6M
NCI NIH HHS R01 CA133322
6 · The paper itself

Abstract

MicroRNAs (miRNAs) play critical roles in regulating cancer cell proliferation, migration, survival and sensitivity to chemotherapy. The potential application of using miRNAs for cancer prognosis holds great promise but miRNAs with predictive value remain to be identified and underlying mechanisms of how they promote or suppress tumorigenesis are not completely understood. Here, we show a strong correlation between miR203 expression and brain cancer patient survival. Low miR203 expression is found in subsets of brain cancer patients, especially glioblastoma. Ectopic miR203 expression in glioblastoma cell lines inhibited cell proliferation and migration, increased sensitivity to apoptosis induced by interferon or temozolomide in vitro, and inhibited tumorigenesis in vivo. We further show that STAT1 is a direct functional target of miR203, and miR203 level is negatively correlated with STAT1 expression in brain cancer patients. Knockdown of STAT1 expression mimicked the effect of overexpression of miR203 in glioblastoma cell lines, and inhibited cell proliferation and migration, increased sensitivity to apoptosis induced by IFN or temozolomide in vitro, and inhibited glioblastoma tumorigenesis in vivo. High STAT1 expression significantly correlated with poor survival in brain cancer patients. Mechanistically, we found that enforced miR203 expression in glioblastoma suppressed STAT1 expression directly, as well as that of a number of STAT1 regulated genes. Taken together, our data suggest that miR203 acts as a tumor suppressor in glioblastoma by suppressing the pro-tumorigenic action of STAT1. MiR203 may serve as a predictive biomarker and potential therapeutic target in subsets of cancer patients with low miR203 expression.

Indexed as

ApoptosisCell MovementCell ProliferationAnimalsAntineoplastic AgentsBrain NeoplasmsCell Line, TumorDacarbazineDose-Response Relationship, DrugGene Expression Regulation, NeoplasticGlioblastomaHumansInterferonsMaleMice, Inbred NODMicroRNAsAntineoplastic AgentsDacarbazineInterferonsMicroRNAsMIRN203 microRNA, humanSTAT1 protein, humanSTAT1 Transcription FactorTemozolomideapoptosisglioblastomamiR203STAT1tumorigenesis

Identifiers

PMID27705947
PMCPMC5341291
OpenAlexW2527353113

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.